Here, we evaluate the existing data on radiation omission in HER2+ BC by using the National Cancer Database (NCDB) to test that hypothesis that RT omission results in equivalent overall survival (OS) in stage I (T1N0) HER2+ BC treated with lumpectomy and adjuvant trastuzumab-based systemic therapy. The gene discussed is ERBB2; the disease is breast cancer.